Phathom Pharmaceuticals, Inc. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Phathom reported Q2 2026 net revenues of $74.3M (88% increase vs Q2 2025; 27% vs Q1 2026), with ~1.7M total VOQUEZNA prescriptions filled. Operating expenses fell 33% YoY to $63.1M; non-GAAP adjusted net loss was $0.1M (vs $56.5M loss in Q2 2025). Company revised full-year 2026 guidance down to $310–325M revenue (from $320–345M) and non-GAAP opex $235–245M (from $235–255M), citing 'more moderate' H2 growth. Cash position $182.5M; company initiated Phase 3 as-needed VOQUEZNA trial for NERD and completed EoE Phase 2 enrollment.
Why this rating
Strong revenue growth and near-breakeven profitability are material; guidance cut tempers optimism. ~$74M quarterly revenue is 26% of market cap annualized, meaningful but not transformational. Execution risk and guidance downside offset strong YoY momentum.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.